Aurinia Pharma GAAP EPS of -$0.25 misses by $0.03, revenue of $28.2M beats by $1.16M

Aug. 04, 2022 6:01 AM ETAurinia Pharmaceuticals Inc. (AUPH)By: Gaurav Batavia, SA News Editor11 Comments
  • Aurinia Pharma press release (NASDAQ:AUPH): Q2 GAAP EPS of -$0.25 misses by $0.03.
  • Revenue of $28.2M (+326.0% Y/Y) beats by $1.16M.
  • Maintains net revenue guidance range of $115-$135 million from sales of LUPKYNIS (voclosporin) for 2022

Recommended For You

Comments (11)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.